Primary targets of the application in cancer immunotherapy and immunization against SARS-CoV-2
ImmunoRec was founded on July 22, 2021 to undertake the application of the “implantable vaccine” technology in humans starting with cancer immunotherapy and the prophylactic vaccine against SARS-CoV-2.
This technology is based on the sensitization of the immune system out of the body (in culture, in vitro) according to the needs of each individual, on top of a biomimetic silicon surface, which after subdermal implantation initiates an immune response against the antigenic stimulus that was given in culture. Thus, in cancer, this antigenic factor is the patient’s own biopsy and the developing immune response is both cellular (development of T cytotoxic cells against the tumor capable of killing tumor cells) and humoral immunity (i.e. production of tumor-specific antibodies). In the case of SARS-CoV-2, the antigenic agent is a reservoir of inactivated viruses and the developing response is again both cellular and humoral.
The technology of personalized implantable vaccines was designed to developing safe and effective prophylactic immunity in the individual. The effectiveness of this technology is based on the natural selection of the optimal antigen epitopes for each type of MHC (HLA in humans) and the application of the optimal dose of antigen for each individual. Safety is based on avoidance of infectivity and the use of adjuvants.
Pre-clinical studies in both applications have been completed and have already been categorized for implementation in clinical trials by the National Medicinal Agency (EOF) and the European Medicinal Agency / Committee for Advanced Therapies, EMA / CAT), respectively.
The application of the technology to cancer has been described by EOF as “immunotherapy against cancer with active substance autologous macrophages, pre-activated against autologous cancer antigens, adsorbed on silicon surface” and is classified as combined Advanced Therapy Medicinal Product-combined ATMP.
The application of the technology to SARS-CoV-2 vaccination has been identified by EMA / CAT as “Autologous antigen presenting cells activated in vitro with inactivated / lysate of SARS-CoV-2 seeded on a 3D silicon matrix” and is classified as Somatic cell therapy medicinal product and combined Advanced Therapy Medicinal Product- combined ATMP.
Especially for the completion of the pre-clinical studies on SARS-CoV-2, we owe a big appreciation to individuals who supported the purchase of consumables for the completion of experiments.
Looking forward to some sponsorships, we expect shortly to submit the Phase I clinical trial for the application of technology in cancer, and in the next 6-8 months the submission of the Phase I clinical trial for the vaccine against SARS-CoV -2.